Top

Published in:

01-03-2017 | Topic Paper

Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review

Authors: Aurélie Mbeutcha, Morgan Rouprêt, Ashish M. Kamat, Pierre I. Karakiewicz, Nathan Lawrentschuk, Giacomo Novara, Jay D. Raman, Christian Seitz, Evanguelos Xylinas, Shahrokh F. Shariat

Published in: World Journal of Urology | Issue 3/2017

Abstract

Background

Upper tract urothelial carcinoma (UTUC) is a rare and heterogeneous disease. Several clinical and biological prognostic factors have been identified in multi-institutional collaborative works with the aim of helping decision-making in pursuit of tailored individual patient care. This review provides an overview of these existing prognostic factors and predictive tools for the management of patients with UTUC.

Methods

A systematic literature search was performed using PubMed/MEDLINE, Web of Science and Scopus databases regarding articles published in English between January 2000 and November 2015 according to PRISMA guidelines. Thresholds of 100 and 300 patients were applied for studies on biomarkers and clinical studies, respectively. All the studies on predictive tools were included for analysis. Outcomes of interest were features associated with advanced-stage UTUC, disease recurrence and survival.

Results

A total of 116 studies were included in this review. These large and/or multi-institutional studies have confirmed the prognostic value of standard pathological factors (i.e., tumor stage, grade and lymph node metastasis) and identified novel features such as lymphovascular invasion, tumor architecture, multifocality, concomitant CIS, variant histology and biomarker status among others. Based on these variables, several predictive tools have been developed; however, they often lack of validation. The value of these features and tools needs prospective testing.

Conclusion

Efforts provided by international collaboration groups have permitted to validate established features and identify new features of biologically and clinically aggressive UTUC. Further investigation on prognostic factors and biomarkers is still needed to assess the benefit of these features and tools on clinical decision-making.

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29PubMedCrossRef

Rouprêt M et al (2015) European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 update. Eur Urol doi:10.1016/j.eururo.2015.06.044

Rai BP, Shelley M, Coles B, Somani B, Nabi G (2012) Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review. BJU Int 110:1426–1435PubMedCrossRef

Bagrodia A et al (2013) Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma. Urology 81:972–977PubMedCrossRef

Rink M et al (2012) Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol 62:677–684PubMedCrossRef

Lughezzani G et al (2012) Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 62:100–114PubMedCrossRef

Committee 2, Rouprêt M, Kamat A, Karakiewicz P, Khochikar M, Lawrentschuk N, Novara G, Raman JD, Schwentner C, Seitz C, Stephenson A, Thompson H, Xylinas E, Shariat SF (2014) Prognostics factors and predictive tools in UTUC. In: Shariat SF, Matin S, Stenzl A (eds) Upper tract urothelial carcinoma. Société Internationale d’Urologie Montréal, QC, pp 51–75

Hutton B et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Int Med 162:777–784PubMedCrossRef

OCEBM Levels of Evidence Working Group = Jeremy Howick, Iain Chalmers (James Lind Library), Paul Glasziou, Trish Greenhalgh, Carl Heneghan, Alessandro Liberati, Ivan Moschetti, Bob Phillips, Hazel Thornton, O. G. and M. H. OCEBM Levels of Evidence Working Group. ‘The Oxford Levels of Evidence 2’. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653

10.

Raman JD, Messer J, Sielatycki JA, Hollenbeak CS (2011) Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int 107:1059–1064PubMedCrossRef

11.

Favaretto RL et al (2012) Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 109:77–82PubMedCrossRef

12.

Messer JC et al (2013) Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol 31:904–908PubMedCrossRef

13.

Chen X-P et al (2013) Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China. BJU Int 112:917–924PubMed

14.

Yeh H, Jan H, Wu W, Li C (2015) Concurrent preoperative presence of hydronephrosis and flank pain independently predicts worse outcome of upper tract urothelial carcinoma. PLoS One 10:1–13

15.

Rink M et al (2012) Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int 63:1082–1090

16.

Xylinas E et al (2014) Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int 114:56–61PubMedCrossRef

17.

Shariat SF et al (2010) Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. BJU Int 105:1672–1677PubMedCrossRef

18.

Chromecki TF et al (2011) Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. World J Urol 29:473–480PubMedCrossRef

19.

Yap SA, Schupp CW, Chamie K, Evans CP, Koppie TM (2011) Effect of age on transitional cell carcinoma of the upper urinary tract: presentation, treatment, and outcomes. Urology 78:87–92PubMedCrossRef

20.

Lughezzani G et al (2010) Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the surveillance, epidemiology, and end results database. Urology 75:321–327PubMedCrossRef

21.

Kusuda Y et al (2013) Gender as a significant predictor of intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract following nephroureterectomy. Urol Oncol 31:899–903PubMedCrossRef

22.

Shariat SF et al (2011) Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 29:481–486PubMedCrossRef

23.

Ehdaie B et al (2011) Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. J Urol 186:66–72PubMedPubMedCentralCrossRef

24.

Raman JD et al (2011) Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? Urol Oncol 29:716–723PubMedCrossRef

25.

Brien JC et al (2010) Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 184:69–73PubMedCrossRef

26.

Fritsche H-M et al (2012) Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol 30:666–672PubMedCrossRef

27.

Remzi M et al (2009) Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int 103:307–311PubMedCrossRef

28.

Ouzzane A et al (2011) Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol 60:1258–1265PubMedCrossRef

29.

Otto W et al (2011) Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. World J Urol 29:487–494PubMedCrossRef

30.

Wheat JC et al (2012) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urol Oncol 30:252–258PubMedCrossRef

31.

Masson-Lecomte A et al (2014) Impact of micropapillary histological variant on survival after radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 32:531–537PubMedCrossRef

32.

Shibing Y et al (2015) Effect of concomitant variant histology on the prognosis of patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy. Urol Oncol 33(204):e9–e16

33.

Rink M et al (2012) Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol 188:398–404PubMedCrossRef

34.

Hurel S et al (2013) Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int 111:1199–1207PubMedCrossRef

35.

Novara G et al (2010) Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 57:1064–1071PubMedCrossRef

36.

Kikuchi E et al (2009) Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 27:612–618PubMedCrossRef

37.

Zigeuner R et al (2010) Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 57:575–581PubMedCrossRef

38.

Seitz C et al (2010) Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. J Urol 184:1895–1900PubMedCrossRef

39.

Isbarn H et al (2009) Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J Urol 182:2177–2181PubMedCrossRef

40.

Raman JD et al (2010) Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 57:1072–1079PubMedCrossRef

41.

Favaretto RL et al (2010) The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 58:574–580PubMedPubMedCentralCrossRef

42.

Margulis V et al (2010) Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 184:453–458PubMedCrossRef

43.

Wu Y, Dong Q, Liu L, Han P, Wei Q (2014) The impact of tumor location and multifocality on prognosis for patients with upper tract urothelial carcinoma: a meta-analysis. Sci Rep 4:6361PubMedCrossRef

44.

Liu J et al (2015) Prognostic impact of ALDH1 expression in transitional cell carcinoma of the renal pelvis. Anticancer Res 35:4829–4836PubMed

45.

Krabbe L-M et al (2015) Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract. J Urol 193:1486–1493PubMedCrossRef

46.

Krabbe L-M et al (2014) Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma. J Urol 191:28–34PubMedCrossRef

47.

Chang I-W et al (2015) CDCA5 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. Am J Transl Res 7:710–722PubMedPubMedCentral

48.

Kuroda K et al (2015) Clinical significance of p21-activated kinase 1 expression level in patients with upper urinary tract urothelial carcinoma. Jpn J Clin Oncol 45:103–110PubMedCrossRef

49.

Lee H-Y et al (2015) INHBA overexpression indicates poor prognosis in urothelial carcinoma of urinary bladder and upper tract. J Surg Oncol 111:414–422PubMedCrossRef

50.

Yeh H-C et al (2015) PTP4A3 independently predicts metastasis and survival in upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol. doi:10.1016/j.juro.2015.05.101

51.

Miyata Y, Kanda S, Nomata K, Eguchi J, Kanetake H (2005) Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract. J Urol 173:56–60PubMedCrossRef

52.

Bagrodia A et al (2014) Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma. Urology 84:1134–1140PubMedCrossRef

53.

Yoshimine S et al (2013) Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma. Br J Cancer 108:2312–2320PubMedPubMedCentralCrossRef

54.

Ichimura T et al (2014) Prognostic significance of CD204-positive macrophages in upper urinary tract cancer. Ann Surg Oncol 21:2105–2112PubMedCrossRef

55.

Bensalah K, Montorsi F, Shariat SF (2007) Challenges of cancer biomarker profiling. Eur Urol 52:1601–1609PubMedCrossRef

56.

Tanaka N et al (2014) A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy. Ann Surg Oncol 21:4041–4048PubMedCrossRef

57.

Pichler M et al (2014) Validation of the preoperative plasma fibrinogen level as a prognostic factor in a European cohort of patients with localized upper tract urothelial carcinoma. J Urol 191:920–925PubMedCrossRef

58.

Xylinas E et al (2014) Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol 65:650–658PubMedCrossRef

59.

Ishioka J et al (2015) Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU Int 115:705–712PubMedCrossRef

60.

Cha EK et al (2012) Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 61:818–825PubMedCrossRef

61.

Shariat SF et al (2012) Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification. Eur Urol 62:224–231PubMedCrossRef

62.

Margulis V et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115:1224–1233PubMedCrossRef

63.

Ku JH et al (2013) Lymphovascular invasion as a prognostic factor in the upper urinary tract urothelial carcinoma: a systematic review and meta-analysis. Eur J Cancer 49:2665–2680PubMedCrossRef

64.

Rink M et al (2013) Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. BJU Int 112:623–637PubMedCrossRef

65.

Rieken M et al (2014) Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol 40:113–120PubMedCrossRef

66.

Hu C-Y et al (2015) Ureteral involvement and diabetes increase the risk of subsequent bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Biomed Res Int 2015:1–8

67.

Tai Y-S et al (2015) Quality assessment and improvement in diabetes care-an issue now and for the future. Diabetes. Metab Res Rev 31:307–314PubMedCrossRef

68.

Seisen T et al (2015) A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol 67:1122–1133PubMedCrossRef

69.

Yuan H et al (2014) Risk factors for intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis. Urol Oncol Semin Orig Investig 32:989–1002CrossRef

70.

Tanaka N et al (2012) Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma. Br J Cancer 106:290–296PubMedCrossRef

71.

Bozzini G et al (2013) Influence of preoperative hydronephrosis on the outcome of urothelial carcinoma of the upper urinary tract after nephroureterectomy: the results from a multi-institutional French cohort. World J Urol 31:83–91PubMedCrossRef

72.

Williams AK et al (2013) Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. Urol Oncol 31:1161–1165PubMedCrossRef

73.

Catto JWF et al (2007) Behavior of urothelial carcinoma with respect to anatomical location. J Urol 177:1715–1720PubMedCrossRef

74.

Kates M, Badalato GM, Gupta M, McKiernan JM (2012) Secondary bladder cancer after upper tract urothelial carcinoma in the US population. BJU Int 110:1325–1329PubMedCrossRef

75.

Kapoor A et al (2014) The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence. Can Urol Assoc J 8:845–852CrossRef

76.

Seisen T et al (2015) Oncological outcomes of radical nephroureterectomy versus kidney-sparing surgery for elective treatment of clinically organ-confined upper tract urothelial carcinoma of the distal ureter. J Urol. doi:10.1016/j.juro.2015.11.036 PubMed

77.

Xylinas E et al (2014) Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 65:210–217PubMedCrossRef

78.

Chang I-W et al (2015) BCAT1 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. Histopathology. doi:10.1111/his.12778

79.

Chang I-W et al (2015) GPX2 underexpression indicates poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. World J Urol. doi:10.1007/s00345-015-1522-7

80.

Fujita K et al (2015) Preoperative risk stratification for cancer-specific survival of patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy. Int J Clin Oncol 20:156–163PubMedCrossRef

81.

Luo Y, Fu SJ, She DL, Xiong HU, Yang LI (2015) Preoperative C-reactive protein as a prognostic predictor for upper tract urothelial carcinoma: a systematic review and meta-analysis. Mol Clin Oncol 3:924–928PubMedPubMedCentral

82.

Tanaka N et al (2014) The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol 32(48):e19–e26

83.

Ehdaie B, Shariat SF, Savage C, Coleman J, Dalbagni G (2014) Postoperative nomogram for disease recurrence and cancer-specific death for upper tract urothelial carcinoma: comparison to American Joint Committee on Cancer staging classification. Urol J 11:1435–1441PubMed

84.

Youssef RF et al (2015) TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. World J Urol 33:1965–1972PubMedCrossRef

85.

Colin P et al (2014) Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy. World J Urol 32:507–512PubMedCrossRef

86.

Brown GA et al (2006) Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int 98:1176–1180PubMedCrossRef

87.

Martinez-Salamanca JI et al (2012) Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 109:1155–1161PubMedCrossRef

88.

Matsumoto K et al (2011) Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 108:304–309CrossRef

89.

Lughezzani G et al (2010) Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study. Eur Urol 57:956–962PubMedCrossRef

90.

Yafi FA et al (2012) Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int 110:E7–E13PubMedCrossRef

91.

Cheng Y, Huang C, Wu W, Li C (2015) The prognostic significance of inflammation-associated blood cell markers in patients with upper tract urothelial carcinoma. Ann Surg Oncol. doi:10.1245/s10434-015-4781-z

92.

Jeldres C et al (2010) Highly predictive survival nomogram after upper urinary tract urothelial carcinoma. Cancer 116:3774–3784PubMedCrossRef

93.

Seisen T et al (2014) Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. BJU Int 114:733–740PubMedCrossRef

94.

Rouprêt M et al (2013) Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol 189:1662–1669PubMedCrossRef

95.

Ku JH et al (2013) External validation of an online nomogram in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. Br J Cancer 109:1130–1136PubMedPubMedCentralCrossRef

96.

Yates DR et al (2012) Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. Br J Cancer 106:1083–1088PubMedPubMedCentralCrossRef

97.

Youssef RF, Shariat SF, Lotan Y, et al (2011) Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma. Urology 77:861–866. doi:10.1016/j.urology.2010.09.032 PubMedCrossRef

98.

Chromecki TF, Cha EK, Fajkovic H, et al (2012) The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 61:245–253. doi: 10.1016/j.eururo.2011.09.017 PubMedCrossRef

99.

Tang Q, Xiong G, Li X, et al (2015) The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy. World J Urol. doi:10.1007/s00345-015-1715-0

100.

Fan EW, Li C, Wu W, et al (2015) FGF7 over expression is an independent prognosticator in patients with urothelial carcinoma of the upper urinary tract and bladder. J Urol 194:223–229. doi:10.1016/j.juro.2015.01.073 PubMedCrossRef

101.

Liang P-I, Wang Y-H, Wu T-F, et al (2013) IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder. J Clin Pathol 66:573–582. doi:10.1136/jclinpath-2012-201278 PubMedCrossRef

102.

Lee DJ, Xylinas E, Rieken M, et al (2014) Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. Eur Urol 66:379–385. doi:10.1016/j.eururo.2013.12.008 PubMedCrossRef

103.

Shi B, Su B, Fang D, et al (2015) High expression of KPNA2 defines poor prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. BMC Cancer 15:380. doi:10.1186/s12885-015-1369-8 PubMedPubMedCentralCrossRef

104.

Izquierdo L, Ingelmo-Torres M, Mallofre C, et al (2014) Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma. BJU Int 113:813–821. doi:10.1111/bju.12551 PubMedCrossRef

105.

Ke H, Lin H, Li W, et al (2015) High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients. Am J Cancer Res 5:2447–2454PubMedPubMedCentral

106.

Pignot G, Colin P, Zerbib M, et al (2014) Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma. Urol Oncol 32:23.e1–8. doi:10.1016/j.urolonc.2012.08.010

107.

Fang D, Zhang L, Li X, et al (2015) Presence of concomitant non-muscle-invasive bladder cancer in chinese patients with upper tract urothelial carcinoma: risk factors, characteristics, and predictive value. Ann Surg Oncol 22:2789–2798. doi:10.1245/s10434-014-4302-5 PubMedCrossRef

108.

Ouzzane A, Colin P, Ghoneim TP, et al (2013) The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy. World J Urol 31:189–197. doi:10.1007/s00345-012-0983-1 PubMedCrossRef

109.

Colin P, Ouzzane A, Yates DR, et al (2012) Influence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival. Ann Surg Oncol 19:3613–3620. doi:10.1245/s10434-012-2453-9 PubMedCrossRef

110.

Hamada S, Horiguchi A, Asano T, et al (2014) Prognostic impact of fatty acid synthase expression in upper urinary tract urothelial carcinoma. Jpn J Clin Oncol 44:486–492. doi:10.1093/jjco/hyu020 PubMedCrossRef

111.

Sasaki Y, Sasaki T, Kawai T, et al (2014) HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients. Int J Clin Exp Pathol 7:699–708PubMedPubMedCentral

112.

Nakanishi K, Hiroi S, Tominaga S, et al (2005) Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin Cancer Res 11:2583–2590. doi:10.1158/1078-0432.CCR-04-1685 PubMedCrossRef

113.

Wu P, Liu S, Zhang W, et al (2015) Low-level Ki-67 expression as an independent predictor of bladder tumour recurrence in patients with primary upper tract urothelial carcinoma after radical nephroureterectomy. Jpn J Clin Oncol 45:1175–1181. doi:10.1093/jjco/hyv139 PubMedCrossRef

114.

Ku JH, Byun S-S, Jeong H, et al (2013) The role of p53 on survival of upper urinary tract urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer 11:221–228. doi:10.1016/j.clgc.2012.12.009 PubMedCrossRef

115.

Kim M, Moon KC, Choi WS, et al (2015) Prognostic value of systemic inflammatory responses in patients with upper urinary tract urothelial carcinoma. World J Urol. doi:10.1007/s00345-015-1484-9

116.

Bolenz C, Shariat SF, Fernández MI, et al (2009) Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. BJU Int 103:302–306. doi:10.1111/j.1464-410X.2008.07988.x PubMedCrossRef

117.

Hattori S, Kikuchi E, Kosaka T, Miyazaki Y (2015) Relationship between increased expression of the Axl / Gas6 signal cascade and prognosis of patients with upper tract urothelial carcinoma. Ann Surg Oncol. doi:10.1245/s10434-015-4848-x

118.

van Oers JMM, Zwarthoff EC, Rehman I, et al (2009) FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 55:650–657. doi:10.1016/j.eururo.2008.06.013 PubMedCrossRef

119.

Jeon HG, Jeong IG, Bae J, et al (2010) Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. Urology 76:513.e7–513.e12. doi:10.1016/j.urology.2010.03.070

120.

Izquierdo L, Truan D, Mengual L, et al (2010) HER-2/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. Anticancer Res 30:2439–2445PubMed

121.

Ke H-L, Chang L-L, Yang S-F, et al (2011) Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma. Urol Oncol 29:703–709. doi:10.1016/j.urolonc.2009.10.009 PubMedCrossRef

122.

Kamai T, Shirataki H, Nakanishi K, et al (2010) Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer. BMC Cancer 10:164. doi:10.1186/1471-2407-10-164 PubMedPubMedCentralCrossRef

123.

Sakano S, Matsuyama H, Kamiryo Y, et al (2013) Risk group stratification based on preoperative factors to predict survival after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Ann Surg Oncol 20:4389–4396. doi:10.1245/s10434-013-3259-0 PubMedCrossRef

Title: Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review
Authors: Aurélie Mbeutcha
Morgan Rouprêt
Ashish M. Kamat
Pierre I. Karakiewicz
Nathan Lawrentschuk
Giacomo Novara
Jay D. Raman
Christian Seitz
Evanguelos Xylinas
Shahrokh F. Shariat
Publication date: 01-03-2017
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 3/2017
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-016-1826-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2017

Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease

Ligation-free technique for dorsal vascular complex control during laparoscopic radical prostatectomy: a single-center experience from China

Prostate volume reduction following pure transurethral bipolar plasma vaporization and conventional transurethral resection of the prostate: a prospective investigation using transrectal 3D ultrasound volumetry

The uses and outcomes of the Martius fat pad in female urology

Prediction of stone-free status and complication rates after tubeless percutaneous nephrolithotomy: a comparative and retrospective study using three stone-scoring systems and preoperative parameters

The German linguistic validation of the Ureteral Stent Symptoms Questionnaire (USSQ)